摘要
目的：观察１２５Ｉ抗ＡＦＰ抗体导向治疗肝癌的毒副反应、药物体内代谢及近期疗效。方法：采用氯胺Ｔ氧化法制备１２５Ⅰ抗ＡＦＰ抗体，经静脉给药，治疗２１例不能手术切除的原发性肝癌，每例接受１２５Ⅰ的中位剂量为２８９３ＭＢｑ（１００３～７０８９ＭＢｑ）。结果：药物在血浆清除缓慢，第１５天１２５Ⅰ血浓度仍为５２７５±１０５３×１０－４％。药物毒性低，耐受好。治后总有效率（ＣＲ＋ＰＲ＋ＭＲ）为４４４％（８／１８），平均生存１４２个月（４～６０个月），一年生存率为３８９％（７／１８）。结论：１２５Ｉ抗ＡＦＰ抗体治疗肝癌毒性低，耐受性好，安全，易防护，并获得较好的近期疗效。
Objective: To observe
biodistribution, therapeutic effects and toxicside reaction of 125IantiAFP antibody in the therapy
of hepatocellular carcinoma. Methods: 21 cases of HCC were treated with 125antiAFP antibody,
which was made by modified chloraminT method. Drug was administered by intravenous drip.
The median dose of 125in the whole group was 3893 MBq (10037089MBq). Results:
125antiAFP antibody was cleared slowly in plasma. The blood concentration was
5275105310-4%in fifteenth day after the use of the drug. The toxicity of 125antiAFP antibody is
mild and tolerable. After the treatment, overall response rate (CR+PR+MR) was
444%(8/18),average survival was 142 months (460 months).the 1year survival rate was
389%(7/18). Conclusion: The use of 125IantiAFP antibody in the treatment of HCC is effective,
low toxic, safe and easily protectable, so it is worth for further studying.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1999年第3期332-335,共4页
Chinese Journal of Cancer
基金
广西科委资助
关键词
碘125
抗AFP抗体
原发性
肝肿瘤
IantiAFPantibody
Hepatocellular carcinoma
Targeting therapy
